You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
345 Phase 3 study of combination pembrolizumab + olaparib therapy versus enzalutamide/abiraterone in metastatic castration-resistant prostate cancer (mCRPC) after progression on chemotherapy (KEYLYNK-010)

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020147026
Dec 20201603
Jan 20213104
Feb 20212305
Mar 20213707
Apr 202168013
May 20211209
Jun 2021008
Jul 20210010
Aug 2021005
Sep 2021005
Oct 202148026
Nov 202140030
Dec 20212406
Jan 20222205
Feb 20223602
Mar 20224609
Apr 20225607
May 20222408
Jun 20222203
Jul 20222203
Aug 20226209
Sep 20222205
Oct 20221006
Nov 20223204
Dec 20221200
Jan 20232005
Feb 20233203
Mar 20231401
Apr 20231603
May 20231402
Jun 20231004
Jul 20233407
Aug 20231403
Sep 2023602
Oct 20231403
Nov 20233601
Dec 20233002
Jan 20241205
Feb 20244001
Mar 202432029
Apr 202414010
May 20242603
Jun 20241603
Jul 20241804
Aug 20241403
Sep 20243404
Oct 20243606
Nov 20241203
Dec 20244606
Jan 20251804
Feb 2025402
Mar 2025005
Apr 2025006
May 2025009
Jun 2025006
Total13740363